Clinical Trial Update: A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248) [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety, tolerability, and antiretroviral activity of raltegravir (MK-0518) in combination with other ART in Russian children and adolesc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Raltegravir (raltegravir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV Infection | Phase 2 | Status: COMPLETED | Results posted: 2014-07-29